Glanzmann Thrombasthenia May Affect Platelet Production

Glanzmann Thrombasthenia (GT) is usually described as a platelet function disorder. People with GT generally have a normal platelet count, but those platelets cannot properly stick together to form a stable clot.

New research published in Blood suggests the story may be more complicated. Researchers found evidence that the proteins affected in Glanzmann Thrombasthenia may also play a role in how platelets are produced.

What Did the Researchers Find?

Changes in the ITGA2B or ITGB3 genes cause Glanzmann Thrombasthenia. These genes make the platelet receptor known as integrin αIIbβ3, also called GPIIb/IIIa.

This receptor is essential for platelet aggregation, which is the process that allows platelets to bind together during clot formation.

Researchers examined platelet counts from 16 people with genetically confirmed GT. Although GT is traditionally associated with normal platelet counts, 8 of the 16 consistently had platelet counts at the lower end of the normal range.

This led researchers to investigate whether αIIbβ3 could have another role beyond helping platelets stick together.

Could Glanzmann Thrombasthenia Affect Platelet Production?

The researchers used laboratory models of megakaryocytes, the bone marrow cells responsible for producing platelets.

When αIIbβ3 was disrupted, megakaryocytes produced fewer proplatelets, structures involved in creating new platelets. Researchers observed reduced platelet production across several laboratory systems.

This suggests that αIIbβ3 may be involved in platelet production as well as platelet function.

What Does Serine Have to Do With GT?

One of the most interesting findings involved serine metabolism.

Serine is an amino acid that cells use for several important biological processes. Researchers found that megakaryocytes lacking normal αIIbβ3 showed changes in how they processed and absorbed serine.

They also found reduced levels of CD98hc, a protein that transports amino acids into cells. When researchers restored normal ITGB3 in the laboratory model, CD98hc levels, serine uptake, and proplatelet formation improved.

This points to a previously unknown connection between αIIbβ3, cellular metabolism, and platelet production.

Does This Mean People With GT Have Low Platelet Counts?

No.

The study does not show that everyone with Glanzmann Thrombasthenia has a low platelet count.

Classic GT is still generally associated with platelet counts within the normal range. In this particular group, half of the 16 patients had counts that consistently fell toward the lower end of that range.

The study was also small, and much of the research investigating why this might occur was performed using laboratory cell models.

Larger studies involving people with GT will be needed to determine how important this finding is in everyday clinical care.

Why Is This GT Research Important?

For decades, Glanzmann Thrombasthenia has primarily been understood as a disorder in which platelets are present but cannot aggregate normally.

This research suggests αIIbβ3 may have a broader biological role than previously recognized.

Rather than affecting only what platelets do after they are produced, changes in αIIbβ3 may also influence the process by which megakaryocytes create platelets.

That does not immediately change how GT is diagnosed or treated. However, understanding these underlying biological processes could help researchers build a more complete picture of Glanzmann Thrombasthenia.

What Should People With Glanzmann Thrombasthenia Take From This Study?

The main takeaway is not that people with GT should expect low platelet counts.

Rather, this study provides evidence that the αIIbβ3 receptor affected in GT may be involved in both platelet function and platelet formation.

It is an important new piece of GT research, but additional studies are needed to determine what these findings mean for people living with Glanzmann Thrombasthenia.

SOURCE